Abstract 3443: Targeting G2/M cell cycle regulators in medulloblastoma tumor-propagating cells

Abstract

Abstract Medulloblastoma is the most common malignant brain tumor in children. While the current treatment strategy of surgery, radiation and chemotherapy has a 60-80% cure rate, the survivors suffer severe side effects, including growth delays and cognitive deficits. Therefore, more effective, less toxic treatments are needed. One approach to achieving this is targeting the cells within a tumor that are capable of re-populating the tumor, known as tumor-propagating cells (TPCs). In the patched mutant mouse model of medulloblastoma, TPCs are marked by expression of the cell surface carbohydrate antigen CD15. Our previous studies suggest that CD15+ cells display increased expression of genes associated with G2/M phase of the cell cycle. Cell cycle analysis suggests that these CD15+ cells move quickly through the G1 and S phases of the cell cycle, but accumulate in G2/M phase. Therefore, inhibition of G2/M regulators, such as Aurora kinases, may represent one approach to targeting TPCs in these tumors. Treatment of tumor cells with the Aurora kinase inhibitor VX-680 (tozasertib) leads to inhibition of proliferation in vitro, with arrest in G2/M and apoptosis. Preliminary studies suggest that patched mutant tumors are also sensitive to Aurora kinase inhibition in vivo. Our findings suggest that targeting Aurora kinases may represent a novel approach for the treatment of hedgehog-associated human medulloblastoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3443. doi:10.1158/1538-7445.AM2011-3443